Related Experiment Video
Updated: Aug 4, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 28, 2007
Janet Woodcock discusses the FDA and the drug development process. Interview by Christopher Watson
1Center for Drug Evaluation and Research, US Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, USA.
Abstract:
Currently Acting Deputy Commissioner for Operations at FDA, Janet Woodcock has served as Director, Center for Drug Evaluation and Research at FDA since 1994. She previously served in other positions in FDA including Director, Office of Therapeutics Research and Review and Acting Deputy Director, Center for Biologics Evaluation and Research. She received her MD from Northwestern Medical School and held faculty appointments at the Pennsylvania State University and the University of California in San Francisco. She joined FDA in 1986.
More Related Videos
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
Related Concept Videos
Drug Discovery: Overview
Clinical Trials: Overview
Drug Regulation
Preclinical Development: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
FDA Approved Drugs: Changes to Approved Drugs